Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 8,881

Document Document Title
WO/2008/065247A1
Class A beta-lactamase may be used for reducing side- effects in the intestine associated with antibiotic therapy with a combination of beta-iactam antibiotic and beta- lactamase inhibitor.  
WO/2008/065891A1
Administration of either a tocopherol represented by the general formula (1) or a tocotrienol compound ester derivative before or after exposure to radiation is effective in preventing or treating health disorders caused by the radiation...  
WO/2008/062852A1
It is intended to provide a composition for neutralizing the exotoxin of enterohemorrhagic Escherichia coli which comprises a less expensive and easily available source as the main component. This object has been achieved by finding out ...  
WO/2008/062861A1
Disclosed are: an extract powder of an indigo-containing plant, which has a low hygroscopic property, excellent fluidability and high storage stability; a method for producing the extract powder; and a composition comprising the extract ...  
WO/2008/058988A1
The use of a compound of formula (I), is disclosed in treating and/or preventing 5 chemotherapy-induced peripheral neurotoxicity (CIPN). The invention includes pharmaceutical compositions wherein the compound of formula (I) is present in...  
WO/2008/059905A1
It is intended to provide a raw material for an oral product which is capable of exhibiting various functions of an active oxygen eliminating ability, antiallergy and improvement of the skin, useful for beautification and health, and can...  
WO/2008/053920A1
It is intended to provide a granular composition comprising an oily component (A), which contains a hardly water-soluble physiologically active substance and is polydispersed while forming domains in a matrix made of a water-soluble fill...  
WO/2008/049227A1
The present invention provides a multimeric form of a Tie 2 binding peptide monomer, wherein the multimeric form has Tie 2 agonist activity. The multimeric form, preferably a tetramer, stimulates angiogenesis and promotes wound healing. ...  
WO/2008/050789A1
The object is to demonstrate the myocardial protection effect of interleukin-11 in vivo and provide a prophylactic or therapeutic agent for a heart disease or the like comprising interleukin-11 as an active ingredient. Interleukin-11 has...  
WO/2008/051795A3
A water-insoluble cellulose derivative, such as ethyl cellulose is useful for preventing or reducing oxidative stress or oxidative cell injury in tissues of an animal and in particular for influencing the level Stearoyl-CoA Desaturase-1 ...  
WO/2008/051795A2
A water-insoluble cellulose derivative, such as ethyl cellulose is useful for preventing or reducing oxidative stress or oxidative cell injury in tissues of an animal and in particular for influencing the level Stearoyl-CoA Desaturase-1 ...  
WO/2008/050754A1
Disclosed is an intracerebral oxidation inhibitor which can prevent the occurrence of dementia and is effective for early treatment. Specifically disclosed are: an intracerebral oxidation inhibitor comprising a peptide composed of Leu an...  
WO/2008/048134A1
The invention relates to pharmacology, medicine and opthalmology, in particular to chemical compounds having a structure (I) and to solvates, isomers or pro-pharmaceutical forms thereof used in pharmaceutical compositions which contain p...  
WO/2008/043782A2
The use of CD1 B, or CD1 D, respectively as a target for a disorder selected from Systemic Lupus Erythematosus (SLE), Lupus Anticoagulant (LA) Rheumatoid Arthritis (RA) and Idiopathic Thrombocytopenic Purpura, and the use of CD1 D as a t...  
WO/2008/041012A1
Pharmaceutical compositions comprising an antibody which binds specifically to a target toxin and a large binding fragment of an antibody which binds specifically to said toxin are described and claimed. The compositions are particularly...  
WO/2008/043102A2  
WO/2008/043081A2
The present invention provides novel stable, liquid compositions comprising chalcogenides or salts thereof. These compositions may be used for a variety of purposes, including the treatment and prevention of ischemic or hypoxic injury, a...  
WO/2008/043081A3
The present invention provides novel stable, liquid compositions comprising chalcogenides or salts thereof. These compositions may be used for a variety of purposes, including the treatment and prevention of ischemic or hypoxic injury, a...  
WO/2008/035572A1
Disclosed are a moisturizing agent, an anti-aging agent, a skin-whitening agent, an anti-inflammatory agent and an antioxidant agent, each of which comprises a plant belonging to the genus Barringtonia or Couroupita or an extract thereof...  
WO/2008/034316A1
The present invention discloses a compound preparation for reducing oxidative stress rapidly, which comprises micromolecule compounds capable of eliminating free radical and regulating endocrine system and digestive system, mineral micro...  
WO/2008/035583A1
Disclosed are a moisturizing agent, a cell-activating agent, an antioxidant agent, a protease activity-enhancing agent, an anti-aging agent, a skin-whitening agent, an anti-inflammatory agent, and a neutral fat accumulation-inhibiting ag...  
WO/2008/036056A1
The inventive method for producing a sorbent consists in adding a strong acid solution to a methylsiliconate sodium (or potassium) solution for obtaining a product, which after being stabilised, is ground and activated by adding a strong...  
WO/2008/036056A9
The inventive method for producing a sorbent consists in adding a strong acid solution to a methylsiliconate sodium (or potassium) solution for obtaining a product, which after being stabilised, is ground and activated by adding a strong...  
WO/2008/035566A1
A cell activator, a collagen production promoter, a collagenase activity inhibitor, a melanin formation inhibitor, an antioxidant agent, an antiinflammatory agent, a fat accumulation inhibitor, a protease activity promoter, an external p...  
WO/2008/033545A2
The present invention is directed to the use of a compound having the formula (I), wherein R1, R2, R3, m, n and p are defined herein. The compounds of the present invention are useful as inhibitors of certain taste perceptions and functi...  
WO/2008/029877A1
Disclosed are an anti-aging agent, a skin-whitening agent, an anti-oxidative agent and an anti-inflammatory agent, each comprising a plant Glias nueberthii or an extract thereof as an active ingredient. Further disclosed are various comp...  
WO/2008/029879A1
A moisturizing agent, a cell-activating agent and an antioxidant containing as an active ingredient one or more types of plants selected from the plants of the Molluginaceae genus or an extract thereof are disclosed. Further, various com...  
WO/2008/026904A1
The invention relates to an antidote composition which is used to treat a patient suffering from poisoning resulting from the inoculation of venomous substances following a sting or a bite from a poisonous animal. According to the invent...  
WO/2008/025163A1
The present invention provides AMPAR excitotoxicity mediating polypeptides comprising the GluR2 NT1 -3-2 (Y142-K172) amino acid sequence (SEQ ID NO:1) or the GAPDH(2-2-1-1) (I221-E250)amino acid sequence (SEQ ID NO:2). Also disclosed are...  
WO/2008/022365A3
The use of galanthamine of the formula (I) and derivatives or analogues of galanthamine for controlling the effect of toxic organic phosphorus compounds such as parathion, paraxon, sarin, soman or tabun is described, wherein a compositio...  
WO/2008/024021A1
The invention relates to the pharmaceutical industry and to medicine, in particular to a novel highly active antioxidant which is used for preventing and treating diseases caused by oxidative stress and scarcity of oxygen in an organism ...  
WO/2008/022365A2
The use of galanthamine of the formula (I) and derivatives or analogues of galanthamine for controlling the effect of toxic organic phosphorus compounds such as parathion, paraxon, sarin, soman or tabun is described, wherein a compositio...  
WO/2008/018133A1
The invention relates to a moisturizing agent, a cell-activating agent, a skin-whitening agent, an agent for suppressing triglyceride accumulation and an antioxidant containing as an active ingredient, one or more plants selected from pl...  
WO/2008/018142A1
It is intended to provide a composition which exerts an excellent antioxidant effect in vivo. Namely, an antioxidant composition characterized by containing a component originating in the bark of a tree belonging to the genus Acacia.  
WO/2008/015867A1
Disclosed is a method for activating dissolved hydrogen molecules in water and stabilizing the hydrogen molecule concentration. Specifically disclosed is a method for activating and stabilizing dissolved hydrogen molecules in water, whic...  
WO/2008/016378A3
The present invention relates to methods useful for treating and/ or preventing radiation- and/ or chemical-induced toxicity in non-malignant tissue using a protease activated receptor- 1 (PAR-I) inhibitor. In particular, use of a protea...  
WO/2008/016378A2
The present invention relates to methods useful for treating and/ or preventing radiation- and/ or chemical-induced toxicity in non-malignant tissue using a protease activated receptor- 1 (PAR-I) inhibitor. In particular, use of a protea...  
WO/2008/016123A1
Disclosed is a GSK-3β inhibitor comprising an oxadiazole compound or a salt or prodrug thereof which is useful as a prophylactic/therapeutic agent for a GSK-3β-related condition or disease. The GSK-3β inhibitor comprises a compound re...  
WO/2008/013219A1
Disclosed is a composition which enables the increased in-vivo absorption of cryptoxanthin derived from a natural product, particularly cryptoxanthin derived from Unshu-orange which is known to contain cryptoxanthin in a large quantity. ...  
WO/2008/010403A1
The invention is directed to a method for preventing coloration of catechins by adding to catechins, a water-soluble polymer capable of forming a water-insoluble complex with catechins; and hydrogel particles containing a water-insoluble...  
WO/2007/147590A3
The present invention concerns a solution and methods to reduce, treat and/or prevent oxidative stress and cell activation. According to the invention the solution gives rise to the following concentrations of constituents within a blood...  
WO/2007/147590A2
The present invention concerns a solution and methods to reduce, treat and/or prevent oxidative stress and cell activation. According to the invention the solution gives rise to the following concentrations of constituents within a blood...  
WO/2007/145682A1
A composition for oral radionuclide chelation therapy comprises a DTPA chelate selected from Zn-DTPA and Ca-DTPA and a permeation enhancer that preferentially increases jejunal uptake of the DTPA chelate. The composition has a DTPA chela...  
WO/2007/143858A1
Diphtheria and Pseudomonas infections are very common worldwide. The toxins involved in the pathogenesis of those diseases act by inactivating the elongation factor-2 (EF-2), therefore blocking protein synthesis and leading to cell death...  
WO/2007/143851A1
The present application concerns plant extracts which have been fermented with kephir grains, methods of production of these extracts, a powder comprising these extracts and compositions comprising these extracts. Since these extracts ha...  
WO/2007/140551A2
The present invention relates to the use of vanilloid receptor (VR) antagonists, and more particularly vanilloid receptor 1 (VR1) antagonist, as analgesics in the treatment and/or prohylaxis of cnidaria envenomations.  
WO/2007/143066A2
Provided is a method for determining whether an individual is likely to be susceptible to radiation pneumonitis from radiation therapy and for developing a treatment based on the determination of susceptibility. The method involves measu...  
WO/2007/140551A3
The present invention relates to the use of vanilloid receptor (VR) antagonists, and more particularly vanilloid receptor 1 (VR1) antagonist, as analgesics in the treatment and/or prohylaxis of cnidaria envenomations.  
WO/2007/139153A1
It is intended to provide a function-improving agent for cerebral dysfunction caused by an environmental chemical. According to the invention, the function-improving agent for cerebral dysfunction caused by an environmental chemical cont...  
WO/2007/135241A3
This invention relates to a non-toxic composition which bind acetaldehyde present in the stomach, intestine and/or colon. The composition comprises one or more acetaldehyde-binding compound(s) comprising one or more free sulphhydryl and/...  

Matches 551 - 600 out of 8,881